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Abstract: The ability of ferritin to bind and deliver metals and metal-based drugs to human
neuroblastoma SH-SY5Y cells was studied. We used heavy chain (H) ferritin-based metal-containing
nanocarriers to test whether these constructs, which are able to cross the blood-brain barrier,
may be used for the delivery of toxic molecules to brain cells, and to study their effect
on the viability and cellular redox homeostasis of human neuroblastoma cells. We show
that metal-containing nanocarriers are efficiently captured by SH-SY5Y cells. Iron-containing
nanocarriers have a proliferative effect, while silver and cisplatin-encapsulated nanocarriers
determine concentration-dependent neuroblastoma cell death. This work is a proof of concept
for the use of ferritins for the delivery of toxic molecules to brain tumors.
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1. Introduction
Nanocarrier (NC) systems are suitable for several applications, including cell-specific or
tissue-specific drug delivery, biomedical imaging and therapy [1,2]. Many types of materials are
used for the synthesis of NC: among these, special attention is given to protein cage structures,
such as ferritins (Fts), because they are self-assembling, highly symmetrical proteins, with a strictly
controlled size.
Fts are easy to be expressed and purified at high levels and at low costs in Escherichia coli,
and are exceptionally stable over wide ranges of temperature and pH. Fts are small enough to
penetrate capillary spaces and large enough to avoid renal clearance. Notably, Fts are physiological
materials, very soluble in aqueous solutions and in the blood, with low toxicity, susceptible to chemical
modifications and being modified by molecular biology techniques [3–10]. Materials such as Fe3O4,
Co3O4, Mn3O4, Pt, CoPt, Pd, CdS, CdSe, ZnSe, CaCO3, SrCO3, Au, Ag and BaCO3 have been produced
and characterized in different ferritin templates [11].
Fts are the main intracellular iron storage proteins in both prokaryotes and eukaryotes, and are
large (480 kDa) complexes of 24 subunits, capable of containing as many as 4500 atoms of iron ions
(Fe3+) within a hydrous ferric oxide core [12] (Figure 1). In mammals, two distinct classes of ferritin
subunits exist, heavy (H) and light (L) chains, with molecular weights of about 21 kDa and 19 kDa,
respectively, which share about 54% sequence identity. The H- and L-subunits have different functions,
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in that the L-subunit enhances the stability of the iron core, while the H-subunit is endowed with a
ferroxidase activity that is necessary for the rapid uptake of ferrous iron [13]. The H-subunit is very
important for the organism because the absence of the H-ferritin (HFt) is embryonically lethal [14,15].
In contrast, bacterial ferritins contain a single subunit type that resembles the H chains [16,17].
HFt can deliver iron to many tissues, including the brain [18]. The brain imposes challenges to
iron acquisition because of the highly developed tight junctions that bind neighbouring endothelial
cells that make up the brain microvasculature. These junctions prevent the flux of molecules into the
brain. The resulting blood-brain barrier (BBB) is a highly effective mechanism for protecting the brain
from potentially harmful substances that circulate in the blood. A consequence of such a blockade,
however, is that specific transport mechanisms must be designed for the trophic substances required
for normal brain function. Transferrin and Fts are the main sources of iron for brain cells. Transferrin is
considered the primary mechanism for cellular iron delivery to the brain, and a transferrin-mediated
transport system has been identified in the BBB, based on transferrin receptors (TfRs, or CD71) [19,20].
CD71 was identified in endothelial cells in culture and in rat brain microvasculature [21].
HFt also enters the cells via CD71: upon interaction with CD71, membrane invagination takes
place, with the formation of Ft-containing early endosomes [22]. HFt is, therefore, an important
means for transporting iron across the BBB: in fact, iron can be delivered to the brain also in
hypotransferrinemic mice [23].
CD71 expression is highly dependent on cellular iron requirement, and is increased by 1–2 orders
of magnitude in malignant, metastatic and/or drug resistant tumors (for a review, see [24]). This,
together with the possibility to load Ft with high amount of chemotherapeutics, and the exceptional
physico-chemical properties mentioned above, makes H-subunit Ft-based nanocarriers (HFt-NCs) ideal
vehicles for drug delivery to cancers [4,6]. Our group has recently synthesized Ft-based nanoparticles
(NPs) designed to carry large amounts of drugs [25]. These molecules are able to bind metals and have
been used against leishmaniasis [11,26].
Upon incorporation of chemotherapeutic agents, Ft-based smart nano-transporters have been
developed against neoplastic cells [10,25,27]; these molecules, based on the combination of human
Ft with chemotherapeutic agents (doxorubicin or cisplatin), selectively reach, recognize and kill
cancer cells.
In the present study, we have exploited the ability of HFt to bind different metals, which would be
scarcely soluble in aqueous media, and to deliver via TfR1/CD71 the metals and metal-based drugs to
an established model of the human brain tumor, the SH-SY5Y neuroblastoma cells. We used HFt-NCs
as a proof of concept to test whether these Ft constructs, which are able to pass through the BBB, may
be exploited for the delivery of toxic molecules to brain cells, and to study their effect on the viability
and cellular redox homeostasis of human neuroblastoma cells.
2. Experimental
2.1. Cell Culture
The human neuroblastoma SH-SY5Y cell line was obtained from the ICLC (Genova, Italy). Cells
were grown in Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F-12) medium
(Sigma-Aldrich Corporation, St. Louis, MO, USA) containing 10% foetal bovine serum (Gibco BRL
Life Technologies Inc., Grand Island, NY, USA) and 2 mM L-glutamine (Sigma-Aldrich Corporation,
St. Louis, MO, USA) at 37 ◦C in a humidified atmosphere of 95% air and 5% CO2. Cells were plated
at an appropriate density according to each experimental setting and treated with the indicated
concentration of NP for different times. Appropriate controls with untreated cells or with cells treated
with residual iron-containing Ft particles (see Bacterial Expression and Purification) were run in parallel.
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2.2. Bacterial Expression and Purification
Recombinant human ferritin H chain (HFt) was expressed and purified from E. coli, as previously
described [25] with the addition of one column exchange and one ultracentrifugation step. Samples
dialyzed overnight against phosphate saline buffer (PBS) pH 7.5 were loaded on a strong anion
exchange column HiTrap Q HP (Q Sepharose High Performance GE Healthcare, Boston, MA, USA)
previously equilibrated with the same buffer. In these conditions, HFt samples eluted from the column,
whereas other E. coli proteins and DNA contaminants did not. The recovered HFt samples were
ultracentrifuged at 100,000× g for 55 min at 6 ◦C using a Beckman L8-70M ultracentrifuge (Beckman
Coulter, Brea, CA, USA). The recovered supernatant was then precipitated using ammonium sulphate
at 65% saturation (w/v). The pellet was resuspended and dialyzed overnight against PBS, pH 7.5,
pooled, concentrated by using concentration tubes with cut-off 30 kDa Amicon Ultra-15 centrifugal
filter devices, according to the manufacturer instructions (Millipore, Billerica, MA, USA), sterile filtered
and stored at 4 ◦C. Typical yields were 100 mg of pure proteins per 1 L culture. These samples are
characterized by an iron content derived from bacterial growth of about 50 atoms per protein molecule.
The Fe(III) content of the samples was assessed as previously described [28].
The purity of all the preparations was assessed using Coomassie brilliant blue staining of 15%
PAGE gels run in the presence of SDS. Protein concentrations were determined spectrophotometrically
at 280 nm, using a molar extinction coefficient (on a 24-mer basis) of 4.56 × 105 M−1·cm−1 (ProtParam
sofware, https://www.expasy.org).
2.3. Metal-Containing Nanocarrier Preparation
Silver-containing HFt were prepared by adding AgNO3 to the HFt solution (Ag/protein oligomer
molar ratio 300:1) under stirring at room temperature in 10 mM HEPES-NaOH buffer at pH 7.8. After
1 h, the solution was centrifuged at 15,000× g for 30 min, dialyzed and concentrated using 100 kDa
Amicon Ultra-15 centrifugal filter devices (Merck Millipore, Billerica, MA, USA).
The cysteine residues on the external surface of HFt were previously blocked using
N-Ethylmaleimide (NEM)-chemistry to minimize binding of Ag(I) on the protein surface. Briefly, NEM
was used at 10-fold molar excess to Cys residues of HFt in PBS pH 7.0, considering 2 Cys residues per
HFt subunit (48 per 24-mer cage).
Gold-containing HFt were prepared as silver-containing ones, using AuCl3 instead of AgNO3.
Cisplatin-containing HFt were prepared as previously described [25]. Cisplatin (cisPt) content
was quantified using a colorimetric assay based on the reaction of platinum and o-phenylenediamine
(OPDA) [25].
Silver or gold contents were quantified as previously described [11] using graphite furnace atomic
absorption spectrometry (GFAAS) and the Zeeman effect for the background correction. Protein
content was quantified by a previously reported procedure [29].
2.4. Fluorescence Microscopy
Labeling of exposed amines of HFt with rhodamine was performed as previously described [30].
Briefly, HFt solution (2 mg/mL) was incubated with 1 mM of 5(6)-carboxytetramethylrhodamine
N-succinimidyl ester (λex 552 nm, λem 575 nm; Thermo Fisher Scientific, Waltham, MA, USA) in
PBS for 2 h at pH 7.5 and room temperature under stirring in the dark. Subsequently, samples were
filtered, dialyzed and exchanged with double distilled H2O and PBS by using 30 kDa Amicon Ultra-15
centrifugal filter devices to remove excess reagents. The number of dye molecules linked per protein
was determined by absorbance spectroscopy, in accordance with the manufacturer’s instructions,
applying the Lambert-Beer law.
The cellular uptake kinetics of 0.03 mg/mL rhodamine-labeled HFt-metal by SH-SY5Y cells were
determined by time-lapse video recording. Cells seeded at a density of 350,000 cells/well in 35 mm
dishes (ibiTreat, cod. 81156, or glass bottom, cod. 81158, both from Ibidi, Martinsried, Germany)
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or 8-well micro-slides (ibiTreat, cod. 80826, Ibidi, Martinsried, Germany) were observed under an
Eclipse Ti inverted microscope (Nikon, Tokyo, Japan), using a 60× objective (Plan Apo VC 60× Oil
differential interference contrast (DIC), N.A. 1.4 Nikon); during the whole observation, cells were
kept in a microscope stage incubator (Basic WJ, Okolab, Pozzuoli, Italy), at 37 ◦C and 5% CO2. DIC
and fluorescence images were acquired every 20 minutes over 4 h, using a DS-Qi1Mc-U2 camera at
12 bits. Eleven z-stacks were acquired every 0.5 µm over a range of 5 µm, attenuating the fluorescence
lamp intensity to 1/32. Image and movie processing were performed with the software NIS-Elements
AR 4.2 (Nikon). Maximum intensity projection of nine z-stacks (for a total of 4 µm) was obtained for
each image. Calculation of nanocarrier uptake was performed using the Fiji software (ImageJ, Version
2.0.0-rc-43/1.51d), by measuring mean rhodamine fluorescence in four selected areas for each cell and
by subtracting the mean background fluorescence.
2.5. Determination of Cell Viability (MTT Reduction Assay)
Cell viability was determined by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) dye reduction assay. Briefly, cells were plated in 96-well plates at a density of
15,000 cells/well. After treatment with the indicated amount of metal-containing HFt (expressed
as metal concentration), 20 µL/well of a 5 mg/mL solution of MTT (Sigma-Aldrich Corporation,
St. Louis, MO, USA) in PBS was added and cells were incubated at 37 ◦C for 2 h. The supernatants
were then aspirated off and formazan crystals were dissolved with 100 µL/well of DMSO. The optical
density of each well was determined at 570 nm with a reference at 690 nm using a microplate reader
(Appliskan microplate reader, Thermo Scientific, Vantaa, Finland).
2.6. Cell Cycle Assessment by Flow Cytometry
Cells were plated in 6-well plates at a density of 350,000 cells/well and treated for various times
with the indicated amount of metal-containing HFt (expressed as metal concentration). After treatment,
cells were trypsinized, collected by centrifugation and washed with PBS. The pellets were resuspended
in ice-cold 70% ethanol and fixed at 4 ◦C for 48 h. After fixation, the cells were washed and resuspended
in 600 µL of DNA staining reagent containing 180 µg/mL RNase and 50 µg/mL propidium iodide.
Red fluorescence was detected by a flow cytometer (BD Accuri C6, BD Bioscences, Erembodegem,
Belgium) equipped with a 488 nm excitation laser and a 585/40 nm band-pass filter (FL2 channel).
The analysis was performed on 50,000 cells in each sample and the percentage of cells accumulating in
the sub-G1, G0-G1, S and M peaks was calculated after appropriate gating of the cells.
2.7. Measurement of Intracellular Glutathione Levels
Intracellular glutathione (GSH) levels were measured by the use of the monoChloroBimane dye
(mCB). Cells were seeded in 96-well plates at a density of 15,000 cells/well in complete medium
without phenol red. After treatment with the indicated amount of metal-containing HFt (expressed
as metal concentration), cells were stained with mCB for 1 h at 37 ◦C in a humidified incubator.
Fluorescence was then measured in a microplate reader with a λex of 366 nm and a λem of 460 nm.
Blanks without mCB or without cells were run in parallel and autofluorescence subtracted to the test
value. GSH intracellular levels were expressed as a percentage compared to the control cells.
2.8. Measurement of Mitochondrial Membrane Potential
Cells were plated in 6-well plates at a density of 350,000 cells/well and treated for various times
with the indicated amounts of NPs (expressed as metal concentration). After treatment, the cells were
incubated with 2.5 µg/mL JC-1 in culture medium at 37 ◦C for 20 min. After washing with PBS, cells
were collected by trypsinization, centrifuged and washed again in PBS. Cells resuspended in PBS
were analyzed by a flow cytometer equipped with band-pass filters 533/30 nm (FL1 channel) and
585/40 nm (FL2 channel), respectively. At least 50,000 events per sample were collected. Mitochondrial
membrane potential (∆Ψm) (red/green JC-1 fluorescence) was expressed as percentage of the control.
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3. Results
3.1. Synthesis
The synthesis of iron-, silver-, gold- and cisplatin-containing ferritin nanocarriers was carried out
as in Methods, and high yields of stable, purified products were obtained. Silver and gold were used in
the form of their metal salts in order to obtain the non-reduced metal ions directly bound to the ferritin
protein. In this way, these metal ions can act directly on their targets without the need to be oxidized
again intracellularly. Cisplatin was used as such as it is a standard chemotherapeutic molecule. Each
type of nanocarrier contained high amounts of metal bound to the protein (Figure 1). In our hands,
the metal-binding processes allowed for a content of 56 ± 3 molecules of cisPt, 104 ± 5 molecules of
Au and 145 ± 5 molecules of Ag per protein molecule, respectively. The reason for this difference
in loading capacity among the different metals is likely due to the relative number of binding sites
present on the protein cage. All prepared solutions were very stable and able to resist unaltered for
weeks at 4 ◦C (and for hours at 37 ◦C) before treatment (data not shown).
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Figure  1.  Summary  of  the  synthesis  of  metal‐containing  human  ferritin  H  chain  (HFt)‐based 
nanocarriers. 
3.2. Cellular Uptake of Ferritin Nanocarriers 
The cellular uptake of rhodaminated iron‐containing HFt by SH‐SY5Y cells was determined by 
fluorescence microscopy.  Figure  2A  shows  images  taken  after  0,  2,  3  and  4  h  of  exposure  to 
rhodaminated HFt.  The  images  clearly  show  a  time‐dependent  increase  in  the  intracellular  red 
fluorescence,  along  with  a  decrease  of  mean  background  fluorescence.  Part  of  HFt‐NCs  form 
transient aggregates in the culture medium. 
Figure  2B  shows  the  incorporation  kinetics  of  rhodaminated  HFt,  where  each  timepoint 
represents mean rhodamine fluorescence intensity (AU) upon subtraction of the mean background 
fluorescence. The experiment shows that SH‐SY5Y cells efficiently incorporate the HFt. The fitting of 
the  timecourse  shows  that 50% of  the plateau  is  reached after about 2.5 h. A video  showing  the 
cellular uptake of rhodaminated HFt is included in Supplementary Materials. 
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3.2. Cellular Uptake of Ferritin Nanocarriers
The cellular uptake of rhodaminated iron-containing HFt by SH-SY5Y cells was determined
by fluorescence microsc py. Figure 2A sh ws im ges taken after 0, 2, 3 and 4 h of exposure to
rhodaminated HFt. The images clearly show a time-dependent increase in the intracellula red
flu resce ce, along wit a decrease of mean background fluorescence. Part of HF -NCs form transient
aggregates in the culture medium.
Figure 2B shows the incorpo ation kinetics of rhodaminated HFt, where each timepoint represents
mean rhodamine fluorescence intensity (AU) upon subtraction of th mean background fluorescence.
The xperiment shows that SH-SY5Y cells efficientl incorporate the HFt. The fi ting of the timec rse
shows that 50% of the plateau is reac ed after about 2.5 h. A video showing cellular up ake
r oda inated HFt is included in Supplement ry Materials.
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cells were  seeded  in  8‐well‐plates  and  treated with  0.03 mg/mL  rhodaminated HFt. Fluorescence 
images were acquired every 20 min for 4 h. Times: 0, 2, 3, 4 h (see also the Video S1 in Supplementary 
Materials). Scale bar: 10 μm;  (B)  timecourse of  the  increase  in  fluorescence of SH‐SY5Y cells upon 
incubation  of  rhodaminated  HFt.  y‐axis  shows  mean  rhodamine  fluorescence  intensity  (AU) 
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Figure 2. (A) time-lapse experiment of rhodaminated HFt uptake by neuroblastoma cells. SH-SY5Y
cells were seeded in 8-well-plates and treated with 0.03 mg/mL rhodaminated HFt. Fluorescence
images were acquired every 20 min for 4 h. Times: 0, 2, 3, 4 h (see also the Video S1 in Supplementary
Materials). Scale bar: 10 µm; (B) timecourse of the increase in fluorescence of SH-SY5Y cells upon
incubation of rhodaminated HFt. y-axis shows mean rhodamine fluorescence intensity (AU) measured
for each cell, upon subtraction of the mean background fluorescence (average of eight cells).
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3.3. Evaluation of Cell Viability and Cell Cycle Progression in the Presence of Metal-Containing Ferritin
Nanocarriers
Investigations were carried out to determine the effect of the different metal-containing HFt
nanocarriers on the viability of SH-SY5Y cells. Figure 3 shows cellular viability in the presence of
various HFt-metal concentrations, determined by the MTT assay up to 72 h. HFt (containing a small
amount of iron, i.e., about 50 atoms per protein molecule) and HFt-Au (Figure 3A,B, respectively)
did not show any apparent effect on cell viability up to 48 h of treatment. However, a significant
proliferative effect was observed for HFt, and some effect for HFt-Au, for prolonged treatment (72 h).
Conversely, HFt-cisPt and HFt-Ag (Figure 3C,D, respectively) showed a considerable cytotoxicity
as compared to HFt. In the experiments, the cell viability was negatively correlated with metal
concentration in a statistically significant manner. Data reveal that after 48 h or 72 h of exposure to
HFt-cisPt (Figure 3C), cell viability was reduced by about 50% when exposed to 10 µM HFt-cisPt
(p < 0.001 vs. control), and by 60% when HFt-cisPt were present at a final concentration of 30 µM
(p < 0.001 vs. control). The IC50 value for HFt-cisPt was 10 µM after 48 h of treatment, and 8 µM
after 72 h of treatment; these experiments indicated that the toxic effect of HFt-cisPt is mostly reached
within 48 h-treatments.
HFt-Ag (Figure 3D) had a dramatic effect on cell viability within 24 h of treatment even at very
low concentrations, cell viability being lower than 30% upon incubation with 1 µM HFt-Ag. The IC50
value for HFt-Ag was 0.5 µM after 24 h of treatment; cell death is almost total after 48 h or 72 h
treatments. Notably, HFt-Ag was found to be highly cytotoxic even for very short exposure periods,
i.e., 2–4 h (data not shown), and the toxic effect of HFt-Ag was obtained within a shorter timespan
(a few hours) with respect to HFt-cisPt. Conversely, treatment of SH-SY5Y cells with free AgNO3 elicits
cytotoxic effects comparable to HFt-Ag only at higher concentrations (Supplementary Figure S1).
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Figure 3. Cell viability assay on SH-SY5Ycells upon HFt-based nanocarriers exposure: (A): HFt;
(B): HFt-Au; (C): HFt-cisPt and (D): HFt-Ag. For each type of nanocarrier, 24 h, 48 h and 72 h
treatments with six different amounts of nanocarriers were assayed. Each series is formed by the
following amounts of nanocarriers (expressed as metal concentration): control = no NCs; 0.3 µM;
1.0 µM; 3 µM; 10 µM; 30 µM. For each experimental condition, viability percentage with respect to
control is shown. Each point represents the mean value of three different experiments, each of which is
based on eight different points. Standard errors are indicated. Statistical significance assessed by t-test;
* p (t-test) < 0.05; ** p (t-test) < 0.01; *** p (t-test) < 0.001.
The effect of HFt-metal exposure on SH-SY5Ycells was also assayed by flow cytometry, after
staining with propidium iodide dye to evaluate cell cycle progression and apoptosis. Figure 4 shows
that HFt and HFt-Au do not affect cell cycle progression nor significantly modify the subG0-G1
apoptotic fraction, thus confirming our previous observations on the lack of cytotoxicity as assessed
by the TT method. Conversely, both HFt-cisPt and HFt-Ag caused a marked effect on cell cycle
progression and/or cell viability. In particular, 10 µM HFt-Ag treatment induced a marked increase in
the sub-G1 (hypodiploid) fraction of the total cell population, as compared with the control group,
with percentages rising from about 8% to 28% at 24 h. By increasing the incubation time, most cells
die upon treatment with 10 µ HFt-Ag (see Figure 3), thus impairing the analysis of the cell cycle.
Treatment with 10 µM HFt-cisPt also induced a marked increase in the sub-G1 (hypodiploid) fraction
of the total cell population, as compared with the control group, with percentages rising from about
9% at 24 h to 18% at 48 h and to 28% at 72 h. In the same timeframe, while the S fraction in the control
group is in the 10%–12% range, it becomes about 16% at 24 h, 26% at 48 h and 23% at 72 h.
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3.4. Evaluation of Cellular Redox Homeostasis and Mitochondrial Transmembrane Potential in the Presence of
Metal-Containing Ferritin Nanocarriers
Previous work demonstrated that ferritin nanocarriers may induce oxidative stress-dependent
damage to protein and DNA that may contribute to the toxic effect of the metal NCs [31].
The effect of the different metal-containing HFt-nanocarriers on the mitochondrial potential and
on the intracellular glutathione (GSH) content of SH-SY5Y cells was then investigated. While HFt
increases mitochondrial transmembrane potential after 24 and 48 h of incubation, neither treatment
with HFt-cisPt nor with HFt-Au determines appreciable effects (Figure 5A). Administration of HFt-Ag
dramatically destroys the mitochondrial potential, even after only 24 h of treatment.
The changes in GSH levels of SH-SY5Y cells upon administration of nanocarriers corresponding
to 10 µM metal ions were also assessed (Figure 5B). HFt-Ag treatment determines fast and highly
significant (p < 0.001) reduction of GSH content, while HFt-cisPt administration determines a small,
long-term (72 h) reduction of GSH content. Surprisingly, HFt-Au treatment elicits a 30% reduction
(p < 0.05) of GSH content within 4 h, and a remarkable long-term GSH increase of about 120% at 48 h
and 72 h (p < 0.01).
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4. Discussion
The ability of HFt to pass through the BBB and to enter into cells via transferrin receptor, together
with its ability to bind hundreds of metal molecules into very stable complexes, make HFt-based
nanocarriers the ideal candidates for the delivery of toxic molecules to brain tumors.
In the present work, we have studied: (i) the ability of HFt to bind toxic metals into HFt-metal
complexes and the efficiency of HFt-metal complexes production; (ii) the ability of HFt to enter
readily into neuroblastoma SH-SY5Y cells; (iii) the differential effects of iron-, silver, gold- and
cisplatin-containing HFt nanocarriers on cell viability, cell cycle, mitochondrial transmembrane
potential and redox homeostasis.
We have limited the present study to metal-containing compounds in cultures of SH-SY5Y cells,
and have tested the uptake of metal-containing HFt from neuroblastoma cells and the differential
effect of the different metals, among which include the commonly used cisPt, on this cancer cell line.
The natural ability of HFt to bind iron was used to test the efficiency of binding of other metals
and metal-containing compounds. Here, we demonstrate that HFt is able to bind efficiently high
amounts (tens or even hundreds) of molecules of metal ions, and to protect them from the fast release.
These materials are fully soluble in water and buffer solutions. This, together with the high yields and
the overall low-cost production, makes metal-containing HFt-NCs excellent nanocarriers.
The second point tested is the ability of neuroblastoma human cells to internalize HFt-based
nanocarriers from the culture medium. The level of expression of TfR1 (CD71) on the surface of cells
reflects their metabolic requirements for iron [32]. Upregulation of CD71 in cancer cells is associated
with malignant transformation. CD71 expression is particularly increased in metastatic and drug
resistant tumors [33–38]. This makes CD71 both a tumor marker and a possible system for the delivery
of small-molecule drugs to these cells by CD71-mediated endocytosis [39–44]. Recently, CD71 was
identified as the receptor for HFt [22], with distinct binding sites for HFt and transferrin [45]. After
binding of HFt to CD71 on the cell surface, membrane invagination takes place, and vesicles are formed.
HFt is localized sequentially into endosomes and lysosomes [22]. Neuroblastoma cells, including
SH-SY5Y cells, express high levels of CD71 [46,47], and are therefore able to incorporate high amounts
of HFt. Molecules as sodium ascorbate, which are able to decrease the expression of CD71, cause cell
death within 24 h [47].
Here, we show that SH-SY5Y neuroblastoma cells are able to incorporate HFt NCs within hours,
taking advantage of their high levels of expression of transferrin receptors. This result, together with
the presence of a transferrin-mediated vesicle-based transcytosis system through the BBB [19,20,48,49]
makes HFt-based NCs potentially good carriers for toxic molecules to the brain tumors.
Many metals (e.g., sodium, potassium, magnesium, calcium, iron, zinc, copper, manganese,
chromium, molybdenum and selenium) are required for normal biological functions in humans. We
show that HFt containing small amounts of iron is not toxic, and has a slightly proliferative effect.
However, most metals have toxic effects on the cells, and many metal-containing molecules are used in
medicine [50], cisPt being the most commonly used in antitumor therapy. Following administration of
cisPt, one of the chloride ligands is slowly displaced by water, in a process termed aquation, resulting
in [PtCl(H2O)(NH3)2]+. Water is itself easily displaced, allowing the platinum atom to bind to DNA
bases, in particular to guanine. DNA crosslinking often occurs via displacement of the other chloride
ligand, typically by another guanine. CisPt-dependent DNA crosslinking interferes with cell division
and elicits DNA repair mechanisms, which, in turn, activate apoptosis when repair proves impossible.
Our results show that HFt-cisPt nanocarriers are good potential anti-neuroblastoma molecules: the
cytotoxic effect on SH-SY5Y cells is time-dependent and concentration-dependent. As for treatment
with transferrin-conjugated cisplatin [51], HFt-cisPt administration has high antiproliferative activity
(IC50 = 8 µM after 72 h of treatment) and is likely to result in prolonged plasma half-life with respect
to the unconjugated drug. Furthermore, treatment of SH-SY5Y cells with free cisPt elicits slightly more
cytotoxic effects than HFt-cisPt at higher concentrations (above 10 µM, Supplementary Figure S1),
although other studies showed cytotoxicity of cisPt only at very high concentrations (e.g., Refs. [52,53]).
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Silver nanoparticles (AgNPs) have widespread applications in medicine, but there are limited
studies on the potential of AgNPs as anticancer agents, such as a report on the anti-proliferative activity
of AgNPs against human glioblastoma cells (U251) [54,55]. We show that HFt-Ag nanocarriers are very
toxic for neuroblastoma cells, even at low concentrations, induce oxidative stress-dependent damage
and determine cell death: after 48 h treatments, cell viability is <5% after treatment with 1 µM Ag.
Toxicity is therefore very high at lower concentrations than those toxic upon administration of the ion
alone [55]: in fact, treatment of SH-SY5Y cells with free AgNO3 elicits cytotoxic effects comparable to
HFt-Ag only at higher concentrations (Supplementary Figure S1). Due to this high activity, it would be
important to pay particular attention to the future in vivo experiments evaluating the overall toxicity
in the animal models. In fact, differently than cisplatin-based drugs, silver-based drugs for cancer have
been not fully characterized to date.
HFt-Au is not cytotoxic at the concentrations used, do not affect cell cycle nor significantly modify
the subGo-G1 apoptotic fraction. Even more, upon treatment with HFt-Au, the GSH content of the
cells transiently decreases within 4 h of incubation, and increases in the long term, as already observed
in the same cells, upon treatment with polyphenolic crude extract from Brassica oleracea [56]. A possible
explanation is the exceptionally positive reduction potential of gold (E gold = +1.83 V, vs. silver:
+0.80 V, iron: −0.44 V): therefore, HFt-Au could be able to induce a transient oxidative stress that
perturbs GSH homeostasis and may cause a long-term enhanced synthesis of this peptide.
In general, the cytotoxic effect of the HFt–metal complexes is time-dependent and is strictly
related to the metal release from the HFt. Although this is a slow process, the exact release mechanism
of metal ions from HFt is not yet clear. It is possible that the slightly acidic pH present in the endosome
and lysosome vesicles (pH 4.0–6.0) might be a stimulus to the release process. After all, the release of
iron from ferritin is pH-dependent and low pH facilitates the release. In addition, the ultimate fate
of the HFt is the lysosomal compartment, where the protein degradation can produce a massively
metal release.
5. Conclusions
In conclusion, different metal-containing HFt nanocarriers, therefore, have remarkably different
effects on cell viability, cell cycle, mitochondrial transmembrane potential and redox homeostasis.
In particular, silver molecules bound to HFt determine neuroblastoma cell death, at lower
concentrations than metal-based molecules alone. This work is a proof of concept for the use of
ferritins for the delivery of toxic molecules to neuroblastoma, and paves the way for further studies on
the use of H-subunit ferritin-based nanocarriers containing chemotherapeutic molecules for the cure
of brain tumors.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-3417/7/1/101/s1,
Figure S1: Cell viability assay on SH-SY5Y cells upon exposure to cytotoxic metals: AuCl3 (Au); cisPt (Pt) and
AgNO3 (Ag). Forty-eight hours of treatment with different concentrations of metals was assayed. For each
experimental condition, viability percentage with respect to control is shown. Each point represents the mean
value of eight different experimental points. Standard errors are indicated, Video S1: Rhodaminated nanocarrier
uptake by SH-SY5Y cells.
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Abbreviations
NC nanocarriers
NP nanoparticles
Ft Ferritin
HFt human ferritin H chain
TfR transferrin receptor
HFt NCs H-subunit Ft-based nanocarriers
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cisPt cisplatin
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